Precision Therapeutics, Inc. Release: Three Abstracts on the ChemoFx® Drug Response Marker Accepted by American Society of Clinical Oncology

PITTSBURGH--(BUSINESS WIRE)-- Precision Therapeutics announces that the American Society of Clinical Oncology (ASCO) has accepted three individual abstracts that highlight the utility and feasibility of the ChemoFx® Drug Response Marker for patients with gynecologic sarcomas, cervical cancer and ovarian cancer. These abstracts will be published in conjunction with ASCO’s 2012 Annual Symposium, being held June 1-5, 2012 in Chicago, Illinois.